Natixis’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-120,000
| Closed | -$2.22M | – | 1218 |
|
|
2023
Q3 | $2.22M | Buy |
120,000
+110,429
| +1,154% | +$1.25M | 0.02% | 393 |
|
|
2023
Q2 | $106K | Buy |
9,571
+5,808
| +154% | +$80.9K | ﹤0.01% | 793 |
|
|
2023
Q1 | $50.5K | Sell |
3,763
-235
| -6% | -$4.07K | ﹤0.01% | 826 |
|
|
2022
Q4 | $49.5K | Buy |
+3,998
| New | +$56.6K | ﹤0.01% | 924 |
|
|
2021
Q1 | – | Sell |
-10,110
| Closed | -$250K | – | 1212 |
|
|
2020
Q4 | $250K | Buy |
+10,110
| New | +$335K | ﹤0.01% | 976 |
|
|
2019
Q1 | – | Sell |
-14,790
| Closed | -$1.49M | – | 908 |
|
|
2018
Q4 | $1.49M | Buy |
14,790
+7,810
| +112% | +$810K | 0.01% | 465 |
|
|
2018
Q3 | $882K | Sell |
6,980
-1,708
| -20% | -$181K | 0.01% | 580 |
|
|
2018
Q2 | $729K | Buy |
+8,688
| New | +$636K | ﹤0.01% | 650 |
|
|
2018
Q1 | – | Sell |
-3,903
| Closed | -$228K | – | 995 |
|
|
2017
Q4 | $228K | Sell |
3,903
-13,267
| -77% | -$837K | ﹤0.01% | 755 |
|
|
2017
Q3 | $997K | Buy |
+17,170
| New | +$1.85M | 0.01% | 519 |
|
Natixis's ICPT Position: Q4 2023 in Review
Natixis sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 120,000 shares — an estimated $2.22M sold.
Natixis first reported a position in ICPT in Q3 2017 and held it in 10 quarters. The position peaked at $2.22M in Q3 2023. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Natixis reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Natixis sold 120,000 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $2.22M.
- Natixis first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2017 and held it in 10 quarters.
- Natixis's Intercept Pharmaceuticals, Inc. position peaked at $2.22M in Q3 2023.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Natixis's 13F filing for Q4 2023, filed 13 Feb 2024.